Low molecular weight heparin: a practical approach in deep venous thrombosis in palliative care

Deep vein thrombosis (DVT) is one of the many cause of pain in advance cases of carcinoma cervix. The most widely used agent for combating DVT is unfractionated heparin. Aims of this study is to see the efficacy of the use of low molecular weight (LMW) haparin and its practical utility in palliative...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of palliative care Vol. 17; no. 2; pp. 143 - 145
Main Authors Dutta, Samrat, Chattopadhayay, Subrata, Dasgupta, C, Sarkar, Shyamal
Format Journal Article
LanguageEnglish
Published India Medknow Publications and Media Pvt. Ltd 01.05.2011
Scientific Scholar
Medknow Publications
Subjects
Care and treatment
Cervical cancer
Methods
Original
Palliative treatment
Patient outcomes
Practice
Venous thrombosis
India
Lymphedema
Cervix
Heparin
Online AccessGet full text

Cover

More Information
Summary:Deep vein thrombosis (DVT) is one of the many cause of pain in advance cases of carcinoma cervix. The most widely used agent for combating DVT is unfractionated heparin. Aims of this study is to see the efficacy of the use of low molecular weight (LMW) haparin and its practical utility in palliative care settings. Twelve cases of established DVT received enoxaparin at 40 mg/m with warfarin. There was 70% resolution of limb swelling in seven cases. Out of remaining four cases took two months to resolve and one case did not resolve completely. LMV heparin is effective in palliative care setting and also has added advantage of subcutaneous route of administration.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0973-1075
1998-3735
DOI:10.4103/0973-1075.84536